Preclinical and clinical pharmacology of TPA023B, a GABAAreceptor α2/α3 subtype-selective partial agonist
- 15 February 2010
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 25 (3) , 329-344
Abstract
In the accompanying paper we describe how MRK-409 unexpectedly produced sedation in man at relatively low levels of GABAAreceptor occupancy (∼10%). Since it was not clear whether this sedation was mediated via the α2/α3 or α1 GABAAsubtype(s), we characterized the properties of TPA023B, a high-affinity imidazotriazine which, like MRK-409, has partial agonist efficacy at the α2 and α3 subtype but is an antagonist at the α1 subtype, at which MRK-409 has weak partial agonism. TPA023B gave dose- and time-dependent occupancy of rat brain GABAAreceptors as measured using an in vivo [3H]flumazenil binding assay, with 50% occupancy corresponding to a respective dose and plasma drug concentration of 0.09 mg/kg and 19 ng/mL, the latter of which was similar to that observed in mice (25 ng/mL) and comparable to values obtained in baboon and man using [11C]flumazenil PET (10 and 5.8 ng/mL, respectively). TPA023B was anxiolytic in rodent and primate (squirrel monkey) models of anxiety (elevated plus maze, fear-potentiated startle, conditioned suppression of drinking, conditioned emotional response) yet had no significant effects in rodent or primate assays of ataxia and/or myorelaxation (rotarod, chain-pulling, lever pressing), up to doses (10 mg/kg) corresponding to occupancy of greater than 99%. In man, TPA023B was well tolerated at a dose (1.5 mg) that produced occupancy of >50%, suggesting that the sedation previously seen with MRK-409 is due to the partial agonist efficacy of that compound at the α1 subtype, and highlighting the importance of antagonist efficacy at this particular GABAAreceptor population for avoiding sedation in man.Keywords
This publication has 44 references indexed in Scilit:
- RO4938581, a novel cognitive enhancer acting at GABAA α5 subunit-containing receptorsPsychopharmacology, 2008
- Pharmacological Properties of DOV 315,090, an ocinaplon metaboliteBMC Pharmacology, 2008
- Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAAα2,3subtype-selective agonist, compared to lorazepam and placebo in healthy volunteersJournal of Psychopharmacology, 2007
- α5GABAAReceptors Mediate the Amnestic But Not Sedative-Hypnotic Effects of the General Anesthetic EtomidateThe Journal of Neuroscience, 2006
- An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances CognitionThe Journal of Pharmacology and Experimental Therapeutics, 2006
- TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2 H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and PrimatesThe Journal of Pharmacology and Experimental Therapeutics, 2006
- The benzodiazepine binding site of GABAAreceptors as a target for the development of novel anxiolyticsExpert Opinion on Investigational Drugs, 2005
- Anxiogenic properties of an inverse agonist selective for α3 subunit‐containing GABAA receptorsBritish Journal of Pharmacology, 2005
- Contributions of GABAAReceptor Subtype Selectivity to Abuse Liability and Dependence Potential of Pharmacological Treatments for Anxiety and Sleep DisordersCNS Spectrums, 2005
- Trace fear conditioning involves hippocampal α 5 GABA A receptorsProceedings of the National Academy of Sciences, 2002